Farma

stockwalker
15.12.2020 kl 16:00 16721

fra side 18 i presentasjonen.. her refereres til Novartis.. men hvilken betydning bør legges i det ?

2020 highlights growing interest in radiopharmaceuticals

• Nordic Nanovector is well positioned to expand awareness of the benefits of radiopharmaceuticals

• Novartis confirms commitment to build on its late-stage radio-ligand portfolio
– Lutathera in Phase 3 for Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
– 177Lu-PSMA-617 in Phase 3 for Metastatic Castration-resistant Prostate Cancer (mCRPC)

• Fusion Pharmaceuticals nets $197.6M through IPO on Nasdaq in June
– Announces collaboration with AstraZeneca to develop and commercialize next-generation radiopharmaceuticals
and combination therapies in November (targeted alpha therapies)

• POINT Biopharma raises $20M Series A financing in August to develop Lutetium-177 conjugated
radiopharmaceuticals for cancer

• RayzeBio Inc. raises $45M Series A financing in October to develop Actinium-225 conjugated
radiopharmaceuticals
Redigert 21.01.2021 kl 08:20

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.